Abstract: An immunogenic composition for a vaccine against human malaria. The composition contains one or more polypeptides that can be extracted from a schizont form of a human-malaria parasite such as a Plasmodium falciparum. The polypeptides have a molecular weight of 40,000 to 140,000, and they react with protective antibodies which come from a monkey resistant to the malaria parasite and which can, by in vivo transfer to a monkey sensitive to the parasite, protect the sensitive monkey against the parasite.

Abstract: A variant of the LAV virus, designated LAV.sub.MAL and capable of causing AIDS. The cDNA and antigens of the LAV.sub.MAL virus can be used for the diagnosis of AIDS and pre-AIDS.

Abstract: The invention relates to a new variety of retroviruses designated Human Immunodeficiency virus Type II, HIV-II, samples of which have been deposited at CNCM as I-502 and I-532. It also concerns purified forms of the antigens which can be obtained from this virus, in particular from the gp 36 and gp 130-140 proteins. These various antigens are useful in medical diagnosis and kits, in particular by being placed in contact with serum of the patient to be diagnosed. Lastly, the invention relates to immunizing compositions, in particular containing at least one of glycoproteins gp 36 and gp 130-140.

Abstract: The present invention relates to an immunogenic fraction active against bilharzioses. This glycoprotein extracted from hemocyanin of a mollusc, is characterized in that its glucidic fraction represents 5 to 25% of the glycoprotein molecule and in that the molar composition of said glucidic fraction (calculated on the basis of 3 mannose residues) is substantially the following:______________________________________ Monosaccharidic residues ______________________________________ Mannose 3 Galactose 3 to 4 Fucose 2 to 3 Glucose 2 .+-. 0.2 Xylose 0.5-1 N-acetylglucosamine 3-4 N-acetylgalactosamine 2 .+-. 0.3 ______________________________________Use: immunizing compositions against bilharzioses.

Abstract: A new strain of Human Immunodeficiency Virus (HIV), which is the major etiological agent of Acquired Immune Deficiency Syndrome (AIDS), is identified. The new strain, products derived from the new strain, a diagnostic method for detecting antibodies to the strain in biological fluids, and a diagnostic kit for carrying out the method are described.

Abstract: The invention concerns hybridomes producing anti-Leishmania monoclonal antibodies which are characterized by their capacity to inhibit the infection of sarcomatous cells by the promastigote forms of one or more species of Leishmania, when the sarcomatous cells are placed in contact with the said promastigote forms pre-incubated with these monoclonal antibodies under conditions which, in the absence of the said monoclonal antibodies, would lead to an elevated parasitemia in the said cells.These monoclonal antibodies and the proteins of the parasites that they recognize may be used in the operations of leishmanioses detections.

Abstract: The invention concerns a probe for the detection of shigellae and entero-invasive E. coli, containing a nucleic acid sequence originating from the 140 Mdal virulence plasmid of the M 90 T strain of Shigella flexneri; having a maximum size of around 27 kb and including all or part of the 27 kb Bam HI fragment.This probe permits the in vitro diagnosis of syndromes of dysentery or diarrhea, of the Shigellosis type.

Abstract: The invention relates to a new probe for detecting a specified nucleic acid sequence. It consists of a recombinant DNA containing an insert complementary to the nucleic acid sequence to be detected and nuclecic acid sequences derived from the DNA (+) of phage M13, the bases which participate in the composition of this recombinant DNA, in particular the thymine groups, being replaced by 5-bromouracil groups. The invention also relates to a method for manufacturing this probe, this method comprising the culturing of cell hosts, more especially E. coli, which are auxotrophic for thymine in a medium containing a limiting concentration of thymine and containing 5-bromouracil. After the requisite incubation time, the supernatant is removed and the probe is recovered from the bacterial cells.

Abstract: DNA fragment capable of coding for an immunogenic peptide capable of inducing in vivo antibody reacting with anti-poliovirus. It possesses up to the order of 1.2 kilobase pairs and contains a nucleotide sequence coding for the poliovirus VP1 protein.

Abstract: The invention relates to a kit for detecting the presence of a nucleic acid sequence, such as a gene or a gene fragment, in a composition or a specimen supposed to contain it. The kit comprises a probe containing a nucleic acid complementary with the nucleic acid sequence or gene which is sought. The probe bears at least one 7-iodo-N-2-acetylamino-fluorene group covalently fixed at one at least of the bases of this probe.

Abstract: A new viral strain from the cerebrospinal fluid of an HIV seropositive man is identified. The new strain, products derived from the new strain, a diagnostic method for detecting antibodies to the new strain in biological fluids, and a diagnostic kit for carrying out the method are described.

Abstract: Peptides which can be recognized by antibodies acting both against the "C" and "D" particles of the same poliovirus and against the VP-1 structural polypeptides of this capsid of the poliovirus. These peptides comprise the amino acid sequence: Asp Asn Pro Ala Ser Thr Thr Asn Lys Asp Lys Leu; and one or more additional amino acids in a specified sequence.

Abstract: This process involves the use of benzoquinone as cross-linking agent in large excess compared with the substance to be activated. The activation reaction is realized in a homogeneous liquid medium. Said process making it possible for example to couple antibodies to enzymes for determining or detecting said antibodies.The process can be used for the determination of antitetanic antibodies in human serum.

Abstract: The subject of the invention is a process for the preparation of capsular polysaccharides characteristic of Staphylococcus aureus, comprising the use of coagulase-negative strains of staphylococci for the preparation of these polysaccharides.The capsular polysaccharides obtained can be used for the preparation of vaccines against Staphylococcus aureus and diagnostic agents.

Abstract: This method for immunological determination of amines in biological media consists of: (a) reacting a quinone (in particular, p-benzoquinone) with the amine (for example histamine) present in the test sample; (b) introducing into the medium a monoclonal antibody which specifically recognizes the amine-quinone reaction product formed; and (c) determining one of the forms of the monoclonal antibody present. When the quinone is used in the immobilized state, the monoclonal antibody present is determined in its complexed form with the amine-quinone reaction product (direct type method); when the quinone is used in the free state, the monoclonal antibody is determined in its free form (enzymoimmunometric method or competitive immunoenzymatic method).

Abstract: The invention provides a synthetic peptide which reproduces at least 5 of the 11 amino acids common to the .gamma. chain of sub-unit A of cholera toxin and the .gamma. chain of LT toxin of Escherichia coli. It is preferably constituted by a pentadecapeptide which corresponds to the following formula (I): ##STR1## The process of synthesis is by the step by step construction of the peptide chain starting from the C terminal end of said chain, by the successive fixing of the amino acids which constitute the latter. A novel medicament for the treatment of cholera and infectious gastro-enterites comprises said synthetic peptide as active constituent. A diagnosis agent for cholera and/or infectious gastro-enterites comprises a sequence of nucleotides corresponding to the 5 minimum amino acids of the synthetic peptide.

Abstract: Anti-NANBH (anti-non-A, non-B hepatitis) antibody comprises IgM isolated from sera of monkeys artificially infected with extracts of feces from patients known to be suffering from epidemic NANB hepatitis. A process for isolating an antibody of this type is provided. A reagent for detecting epidemic NANB hepatitis comprises the anti-NANBH IgM fixed to a solid support. The reagent is useful for diagnosing epidemic NANB viral hepatitis by forming an immunological complex between the anti-NANBH IgM and antigen in a fecal extract from a patient being diagnosed, and then incubating the immunological complex with enzyme-labeled IgG from serum of a human convalescing from epidemic NANBH. The complex is detected by developing the enzyme.

Abstract: A method for the detection of the mutagen effect of a substance or composition by producing culture of a micro-organism harboring a recombinant of a sfi gene and of a gene coding for a dosable enzyme in the presence of said substance or composition and measuring the activity of the dosable enzyme induced under the control of the sfi gene. When the latter is activated due to the mutagen character of said substance or composition, measuring the activity of a distinct enzyme synthesized by the microorganism and coded by a gene not involved in the activation process of the sfi gene and measuring the variation of the ratio of the activity of the abovesaid dosable enzyme to the activity of said distinct enzyme. Then comparing the variation that of the ratio of the activities of the same enzyme in a culture of the same microorganism, but in the absence of the mutagen substance.

Abstract: The invention concerns 2,N.sup.6 -disubstituted and 2,N.sup.6 -trisubstituted adenosine nucleosides in which the sugar component is substituted at position 3' or position 5' by a phosphite or phosphoramidite group of the formula: ##STR1## R.sub.1 representing a lower alkyl or --(CH.sub.2).sub.n --CN with n being an integer between 1 and 4, and X representing a halogen or an amine group. These nucleosides make it possible to prepare sequences of nucleotides usable, in particular, as probes in the field of analyses and biological extractions.

Abstract: The invention relates to a probe constituted by an oligonucleotide fragment of structure predetermined by the application envisaged, wherein at least a part of the adenine groups therein is replaced by modified adenine groups so that they can form three hydrogen bonds with the reactive groups of thymine or uracil. This probe is useful in the field of biological analyses and extractions.